Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy
Open Access
- 1 March 2023
- journal article
- research article
- Published by Elsevier in Journal of Virus Eradication
- Vol. 9 (1) , 100319
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Natural history of hepatitis CJournal of Hepatology, 2014
- Liver cirrhosisThe Lancet, 2014
- Epidemiology and natural history of HCV infectionNature Reviews Gastroenterology & Hepatology, 2013
- Sofosbuvir for Previously Untreated Chronic Hepatitis C InfectionNew England Journal of Medicine, 2013
- Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsHepatology, 2013
- The burden of liver disease in Europe: A review of available epidemiological dataJournal of Hepatology, 2013
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012
- Performance of the Aspartate Aminotransferase-to-Platelet Ratio Index for the Staging of Hepatitis C-Related Fibrosis: An Updated Meta-Analysis §ΔHepatology, 2010
- Acute Hepatitis C Virus Infection in Young Adult Injection Drug Users: A Prospective Study of Incident Infection, Resolution, and ReinfectionThe Journal of Infectious Diseases, 2009
- Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis CGastroenterology, 2005